Pricing Log in Create free account

Minerva Neurosciences, Inc (NERV) vs Outlook Therapeutics, Inc. (OTLK)

Minerva Neurosciences, Inc and Outlook Therapeutics, Inc. are both Biotechnology companies. Minerva Neurosciences, Inc and Outlook Therapeutics, Inc. are of similar size ($121.7M and $115.6M). Outlook Therapeutics, Inc. has the higher net margin (5,253.4% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Outlook Therapeutics, Inc. leads on 9 and Minerva Neurosciences, Inc on 3.

Valuation

Metric NERV OTLK Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m (73.15) 9.21
Earnings yield (1,207.23%) (213.12%) (33.15%)
Free cash flow yield (24.00%) (84.46%) (25.50%)

Profitability

Metric NERV OTLK Biotechnology median
Gross margin 0.00% 195.62% 65.16%
Operating margin 0.00% 4,781.76% 0.00%
Net margin 0.00% 5,253.40% 0.00%
Free cash flow margin 0.00% 4,826.38% 0.00%
Return on equity 322.05% 256.92% (56.36%)
Return on assets (629.71%) (251.66%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NERV OTLK Biotechnology median
Revenue growth (TTM) — (113.55%) 6.02%
EPS growth (last fiscal year) (18,347.37%) 55.81% 30.26%
Revenue growth, 5-year CAGR — (22.99%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NERV OTLK Biotechnology median
Debt to equity 0.00 (1.75) 0.00
Current ratio 20.14 0.81 4.72
Net debt to EBITDA 5.46 (0.33) 0.96

Dividend

Metric NERV OTLK Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NERV OTLK Biotechnology median
Market cap 115.55m 121.72m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack